Fesomersen在血液透析肾衰竭患者中的II期随机对照试验
本研究为IIb期随机对照试验,纳入308例血液透析的肾衰竭患者,评估fesomersen(每月一次40/80/120 mg)与安慰剂相比对出血和动脉血栓事件的影响。结果显示fesomersen剂量依赖性降低FXI水平,但MB/CRNMB出血率与安慰剂相似(P=0.78);较低FXI水平与透析回路凝血和AV通路血栓减少相关。
要点
- Fesomersen剂量依赖性降低FXI中位水平达53.6%–86.0%。
- MB/CRNMB出血率各组与安慰剂无显著差异(P=0.78)。
- 较低FXI水平与透析回路凝血(P=0.002)和AV通路血栓(P=0.014)减少相关。
核心结论
- 在血液透析肾衰竭患者中,fesomersen剂量依赖性降低FXI水平,且大出血发生率与安慰剂相似。
- 较低FXI水平与透析回路凝血和AV通路血栓减少相关。
研究设计与样本
- IIb期随机对照试验,纳入308例血液透析的肾衰竭患者,随机接受fesomersen 40、80或120 mg每月一次或安慰剂,最长12个月。
- 307例接受研究治疗并纳入分析。
主要发现
- 稳态FXI中位水平降低:40 mg组53.6%,80 mg组71.3%,120 mg组86.0%,安慰剂组1.9%。
- MB/CRNMB事件发生率:40 mg组6.5%,80 mg组5.1%,120 mg组3.9%,安慰剂组4.0%(合并fesomersen vs 安慰剂 P=0.78)。
- 主要动脉血栓事件在各治疗组均为1例(1.3%)。
- MB/CRNMB出血和透析后AV通路出血与预测FXI水平无关。
- 较低预测FXI水平与透析回路凝血减少(P=0.002)和AV通路血栓减少(P=0.014)相关。
关键数值与推荐
- 主要安全终点为MB/CRNMB复合终点。
- 探索性终点包括透析后AV通路出血、主要动脉血栓事件、AV通路血栓和透析回路凝血。
临床怎么用
- Fesomersen可能在不增加大出血的情况下减少透析回路凝血和AV通路血栓,但需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with kidney failure on hemodialysis (KF-HD) are at high risk for both atherothrombotic events and bleeding. This Phase IIb study evaluated the dose-response of fesomersen, an inhibitor of hepatic Factor XI expression, versus placebo, for bleeding and atherothrombosis in patients with KF-HD. Patients were randomized to receive fesomersen 40, 80, or 120 mg once-monthly, or matching placebo, for up to 12 months. The primary safety endpoint was a composite of major bleeding and clinically relevant non-major bleeding (MB/CRNMB). Exploratory endpoints included post-dialysis arterio-venous (AV)-access bleeding, major atherothrombotic events (composite of fatal or non-fatal myocardial infarction, ischemic stroke, acute limb ischemia/major amputation, systemic embolism, symptomatic venous thromboembolism), AV-access thrombosis, and clotting of the hemodialysis circuit. Of 308 participants randomized, 307 received study treatment and were analyzed. Fesomersen led to a dose-dependent and sustained reduction of steady-state median FXI levels by 53.6% (40 mg group), 71.3% (80 mg group), 86.0% (120 mg group), versus 1.9% in the placebo group. MB/CRNMB events occurred in 6.5% (40 mg group), 5.1% (80 mg group), 3.9% (120 mg group), and in 4.0% of those receiving placebo (pooled fesomersen versus placebo P = 0.78). Major atherothrombotic events occurred in 1 patient (1.3%) in each treatment arm. MB/CRNMB bleeding and post-dialysis AV-access bleeding were not related to predicted FXI levels. Lower predicted FXI levels were associated with reductions in hemodialysis circuit clotting (P = 0.002) and AV-access thrombosis (P = 0.014). In patients with KF-HD, fesomersen produced a dose-dependent reduction in FXI levels associated with similar rates of major bleeding compared with placebo. REGISTRATION: URL: https://www.clinicaltrials.gov; unique identifier: NCT04534114.
引用
- Winkelmayer WC, Lensing AWA, Thadhani RI, et al. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024. PMID: 38537676. doi:10.1016/j.kint.2024.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。